Cargando…
Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy
Chemoradiotherapy (CRT) is the standard treatment for locally advanced head and neck cancer; however, CRT may cause post-treatment dysphagia. Transcutaneous electrical sensory stimulation (TESS), developed in recent years for swallowing rehabilitation, is used at many medical facilities. Although TE...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381452/ https://www.ncbi.nlm.nih.gov/pubmed/37511742 http://dx.doi.org/10.3390/jpm13071129 |
_version_ | 1785080447340904448 |
---|---|
author | Hamamoto, Takao Sato, Yuki Yumii, Kohei Chikuie, Nobuyuki Taruya, Takayuki Horibe, Yuichiro Ishino, Takashi Ueda, Tsutomu Takeno, Sachio Yoshimura, Kenichi |
author_facet | Hamamoto, Takao Sato, Yuki Yumii, Kohei Chikuie, Nobuyuki Taruya, Takayuki Horibe, Yuichiro Ishino, Takashi Ueda, Tsutomu Takeno, Sachio Yoshimura, Kenichi |
author_sort | Hamamoto, Takao |
collection | PubMed |
description | Chemoradiotherapy (CRT) is the standard treatment for locally advanced head and neck cancer; however, CRT may cause post-treatment dysphagia. Transcutaneous electrical sensory stimulation (TESS), developed in recent years for swallowing rehabilitation, is used at many medical facilities. Although TESS has been used for dysphagia in several fields, its safety and efficacy in patients with head and neck cancer remain to be clarified. Therefore, this study evaluated the safety of TESS in ten patients with head and neck cancers undergoing CRT. Swallowing rehabilitation intervention and TESS implementation were performed for all patients during CRT. Non-blood-toxicity adverse events (AEs), such as dermatitis and mucositis, occurred during CRT; however, the severity was less than grade 3. No patient experienced pain due to TESS. As survival time analysis using the Kaplan–Meier method for interferential current device implementation rates revealed a feasibility of 100% for up to 60 Gy and a feasibility of 78% for up to 70 Gy, TESS may be feasible until 70 Gy. This study confirmed the feasibility and safety of TESS in the head and neck region during CRT. Although the precise mechanism of TESS on dysphagia remains unclear, its continued use has great potential for improving sensory disturbance. |
format | Online Article Text |
id | pubmed-10381452 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103814522023-07-29 Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy Hamamoto, Takao Sato, Yuki Yumii, Kohei Chikuie, Nobuyuki Taruya, Takayuki Horibe, Yuichiro Ishino, Takashi Ueda, Tsutomu Takeno, Sachio Yoshimura, Kenichi J Pers Med Article Chemoradiotherapy (CRT) is the standard treatment for locally advanced head and neck cancer; however, CRT may cause post-treatment dysphagia. Transcutaneous electrical sensory stimulation (TESS), developed in recent years for swallowing rehabilitation, is used at many medical facilities. Although TESS has been used for dysphagia in several fields, its safety and efficacy in patients with head and neck cancer remain to be clarified. Therefore, this study evaluated the safety of TESS in ten patients with head and neck cancers undergoing CRT. Swallowing rehabilitation intervention and TESS implementation were performed for all patients during CRT. Non-blood-toxicity adverse events (AEs), such as dermatitis and mucositis, occurred during CRT; however, the severity was less than grade 3. No patient experienced pain due to TESS. As survival time analysis using the Kaplan–Meier method for interferential current device implementation rates revealed a feasibility of 100% for up to 60 Gy and a feasibility of 78% for up to 70 Gy, TESS may be feasible until 70 Gy. This study confirmed the feasibility and safety of TESS in the head and neck region during CRT. Although the precise mechanism of TESS on dysphagia remains unclear, its continued use has great potential for improving sensory disturbance. MDPI 2023-07-12 /pmc/articles/PMC10381452/ /pubmed/37511742 http://dx.doi.org/10.3390/jpm13071129 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hamamoto, Takao Sato, Yuki Yumii, Kohei Chikuie, Nobuyuki Taruya, Takayuki Horibe, Yuichiro Ishino, Takashi Ueda, Tsutomu Takeno, Sachio Yoshimura, Kenichi Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy |
title | Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy |
title_full | Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy |
title_fullStr | Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy |
title_full_unstemmed | Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy |
title_short | Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy |
title_sort | evaluation of the safety of percutaneous sensory nerve stimulation in patients with head and neck cancer receiving chemoradiotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381452/ https://www.ncbi.nlm.nih.gov/pubmed/37511742 http://dx.doi.org/10.3390/jpm13071129 |
work_keys_str_mv | AT hamamototakao evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy AT satoyuki evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy AT yumiikohei evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy AT chikuienobuyuki evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy AT taruyatakayuki evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy AT horibeyuichiro evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy AT ishinotakashi evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy AT uedatsutomu evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy AT takenosachio evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy AT yoshimurakenichi evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy |